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In 2019, the American Thoracic Society (ATS) / Infectious Diseases Society of America 
(IDSA) issued a substantial revision of the 2007 guideline on community-acquired 
pneumonia (CAP). Despite generalization of infectious disease guidelines is limited due 
substantial geographic differences in microbiological etiology and antimicrobial resistance, 
the ATS/IDSA guidelines are frequently applied outside the USA. Therefore, this project 
aimed to give a perspective on the ATS/IDSA CAP recommendations related to the 
management of CAP outside of the USA. For this, an expert panel comprised of 14 
international key opinion leaders in the field of CAP from 10 countries across 5 continents, 
who were not involved in the 2019 guideline, was asked to subjectively name the five most 
useful, the most critical and the recommendation that can not be applied to their respective 
region. There was no formal consensus process and the paper reflects different opinions. 
Recommendations welcomed by the vast majority of the international pneumonia experts 
included the abandonment of the concept of “health-care associated pneumonia” (HCAP), 
the more restrictive indication for empiric macrolide treatment in outpatients, the increased 
emphasis on microbiological diagnostics, and addressing the use of corticosteroids. Main 
criticisms included the somewhat arbitrary choice of a 25% resistance threshold for 
outpatient macrolide monotherapy. Experts from areas with elevated mycobacterial 







Treatment recommendations for infectious diseases are usually more complex and particular 
sophisticated than those for other human diseases. In non-infectious diseases, such as 
cardiovascular or neoplastic diseases, different aspects of their pathogenesis are usually 
similar among patients worldwide, and have not (and will not) substantially changed over 
time in light of a relatively slow pace of human evolution. Among infectious diseases, the 
main goal is to identify and kill the pathogen, and protect the host from both early and long-
term complications. The evolution of most of the microorganisms is – compared to humans – 
usually extremely rapid causing substantial spatio-temporal differences. The CoVID-2019 
virus is a current example for that 1. Therefore, guidelines for the management of infectious 
diseases need frequent updates, and may not be easily generalized from country to country 
or even across different regions in the same country. This holds particularly true for 








health issue2.  
 
After more than 10 years since the last American Thoracic Society (ATS)/Infectious Diseases 
Society of America (IDSA) CAP guideline, a substantial revision has been published in 
2019 3,4. Some major changes were made in the methodology including use of the 
Patient/Population, Intervention, Comparison, and Outcome (PICO) framework, and the 
Grading of Recommendations Assessment, Development, and Evaluation (GRADE) format. 
On a personal note, structure and readability of the guideline are excellent. Despite an 
extensive body of literature that has been covered (216 references), the guideline committee 
managed to limit content to 15 pages – an extent that fits well into the busy daily life of 
clinicians. Furthermore, the strictly followed structure of “summary of evidence”, 
“rationalization of recommendation” and “research needed in this area” is very useful for both 
clinicians -who recognize where is still uncertainty regarding state of the art treatment- and 
researchers - who can develop ideas for future clinical studies. Major changes in the 
recommendation were also nicely highlighted for quick review (Table 1). The highly-
formalized GRADE procedure with answers to the selected sixteen PICO questions now 
reflects the current state of the art for guidelines. However, as for all guidelines -since for 
many questions no specific evidence is available - most of the final recommendations tend to 
reflect a consensus of those experts who have been involved in these guidelines. This is 
demonstrated by different conclusions that are sometimes drawn by different researchers on 
the same study. Finally, the committee clearly stated that the 2019 ATS/IDSA CAP guideline 
specifically focus on immunocompetent patients in the United States of America (USA). 
 
The aim of the present project was to give the scientific community an international 
perspective on the 2019 ATS/IDSA CAP guideline recommendations according to pathogen 
epidemiology, populations, healthcare systems, and standard operating procedures related 




An expert panel comprised of 14 international key opinion leaders in the field of CAP from 10 
countries across 5 continents who were not involved in the 2019 ATS/IDSA CAP guideline, 
has been developed. All experts were asked to answer 3 specific questions:  
 
1. What are for you – compared to 2007 – the up to 5 most important useful changes in 








2. What is the recommendation in the 2019 ATS/IDSA CAP guidelines you do in general 
not agree with or that you see most critical? 
3. Are there recommendations in the 2019 ATS/IDSA CAP guidelines that –from your 
perspective- make sense in the context of the US landscape but cannot be 
transferred to your own continent/country? 
 
The following commentary summarizes these statements. We weighed the comments made 
by displaying the number of experts who made the same or similar statement on a certain 
guideline recommendation. Some agreed in general, but mentioned important exceptions 
that we also considered in the text.  Due to the kind of questions asked the displayed number 
does not always mean that the remaining experts had an opposing opinion but sometimes 
did just not comment on this particular recommendation. For details please see the original 
blinded comments in the supplement. There was no formal consensus process and the 
paper reflects different opinions. The expert number of 14 revealed on the one hand some 





The most important changes in new 2019 ATS/IDSA CAP  Guidelines 
 
This section compresses the answers to question #1 and #2. 
 
1) Abandoning the categorization of health-care ass ociated pneumonia 
For most of the experts (13 out of 14; 92.9 %), the abandoning the category “health-care 
associated pneumonia” (HCAP) was the most useful change in the new 2019 ATS/IDSA 
CAP Guidelines. There was broad consensus that the positive predictive value of the HCAP 
definition was far too low to justify empiric antibiotic regimens covering Multi-Drug Resistant 
(MDR) bacteria, and data clearly demonstrates that this classification resulted in 
overtreatment of CAP patients, and may be associated with adverse outcomes including 
increased mortality 5-9.  
The alternative concept of “strong risk factors”, e.g. known colonization of Methicillin-resistant 
Staphylococcus aureus (MRSA) or Pseudomonas aeruginosa, have been recently suggested 
by international experiences and was well received by the present expert panel10. However, 
an overemphasis on these two specific pathogens – MRSA and P. aeruginosa – misses 
emerging data on ESBL-containing Enterobacteriaceae as a cause of CAP 11. Since 








recommendation for more extensive diagnostic testing would be desirable to support 
appropriate antibiotic stewardship according to 6 out of 14 (42.9 %) experts (see below) 12. 
 
2) Recommendation against the use of corticosteroid s  
Prior meta-analyses suggesting a benefit to corticosteroids may have triggered a increased 
usage corticosteroid use13. The guideline committee recognized that differences across 
healthcare systems worldwide, not accounted for in the meta-analyses, may have a marked 
influence on the benefit of corticosteroids on length of stay (LOS) and, therefore, advised 
against the routine use in CAP. Specifically, the dominant use of β-lactam monotherapy and 
longer baseline LOS in the control group of these European studies that was almost twice as 
long as standard in the USA, raising concerns about the generalizability of these results in 
the US-population14. For most of the experts (11 out of 14; 78.6 %), addressing the 
controversy of corticosteroids in CAP is a major benefit of this guideline per se, as this has 
been a confusing area for clinicians. 
 
However, whereas nine out of 14 (64.3 %)  of experts strongly agreed with the wording of the 
recommendation, four experts (of 14; 28.6 %) opposed the guideline recommendation 
against corticosteroids, citing concerns that it limits the treatment options in severe CAP and 
may increase mortality in these patients. Three of those four explicitly criticized the guideline 
summary of corticosteroid treatment as overly simplistic, suggesting that the specific 
indications and risk benefit ratio of use should be distinguished between moderate and 
severe CAP could have been discussed more, where mortality is high and the risk-benefit 
ratio may be different compared to moderate severity. This position was rationalized by 
referring to a study that has shown a benefit in terms of treatment failure measured by 
radiological improvement in selected patients with high inflammation, as reflected by a C-
reactive protein >150mg/L on admission with CAP15. As pneumonia is the leading cause of 
sepsis, substantial overlap exists between community-acquired sepsis and severe CAP16, as 
evidenced by overlapping parameters in sepsis and CAP severity scores (CRB and qSOFA) 
17. Sepsis studies may, therefore, provide some insights in this issue of debate. Although the 
question of which corticosteroid and at what dose and duration was not clearly resolved, the 
stress-dose steroid recommendations of the Surviving Sepsis Campaign were endorsed by 
the CAP guideline committee for patients with refractory septic shock 18.  
 









The use of procalcitonin has always been an issue of debate, and this was also reflected 
among the expert panel. Two experts rated the recommendation against using procalcitonin 
to initiate or withhold empiric antibiotics among the top 5 useful recommendations of the 
novel guideline; they particularly agreed that completely withholding antibiotics might 
underestimate the burden of bacterial super-infections, which are associated with a 
particularly high mortality. In contrast, for two other experts, that recommendation was the 
most critical in the guideline. They argued that the recommendation against the use of 
procalcitonin for initial antibiotic treatment has ignored important studies, and was mainly 
based on a single study which excluded patients with radiological evidence of CAP19. They 
also argued that procalcitonin should be used as one among many pieces of diagnostic data 
to help a clinician justify early discontinuation of antibiotics when other evidence strongly 
supports a primary viral only etiology. One expert suggested that procalcitonin might have 
been recommended at least for shortening antibiotic duration, citing critical care evidence 
that a strategy of early antibiotic discontinuation based on downward procalcitonin trend may 
be an approach that balances patients’ safety versus the aim to decrease unnecessary 
antibiotic usage20, which is in fact mentioned in the guidelines as likely to be useful primarily 
in settings where the average duration of treatment for patients with CAP exceeds normal 
practice. 
 
4) Recommendation for the conditional use of macrol ide monotherapy in outpatients 
based on local resistance levels. 
For most experts this represents a major improvement in the updated guideline. The 
rationale is that outpatients often have a similar pathogen spectrum as inpatients, with the 
exception perhaps of Gram-negative bacilli and Legionella. In outpatients, pneumococci and 
Haemophilus influenzae are often the leading pathogens and are not well targeted with a 
macrolide. H. influenzae exhibits intrinsic resistance to macrolides and macrolide use in 
patients with H. influenzae has been associated with treatment failure21. Most importantly, 
pneumococcal resistance to macrolides varies by region and is high in some areas 
worldwide. The guideline suggests a cut off of 25% of macrolide resistance in pneumococci, 
above which macrolides should not be used. However, half of the experts opposed to the 
25% cut off, stating that this was too liberal and that a cut off of 25% reflects a “dangerous” 
approach that “could demand lives”, given the clear association between macrolide 
resistance and treatment failure. Indeed, the definition of “inadequate spectrum” and an 
acceptable “gap” of the empiric antibiotic treatment has always been a matter of debate. It is 
reasonable to aim for a small “gap” in patients with high severity of disease such as those 
with sepsis - in light of the fact that numerous studies have shown that failing to cover the 







contrast, the consequences of an inadequate spectrum in patients with mild CAP may not be 
as dramatic, especially considering that a substantial proportion may have a primary viral 
etiology 23. In addition, given the roughly one third of pneumococcal etiology, a margin of 
25% would result in an “overall gap” of much less than 25% and seems reasonable in an 
outpatient population with an overall very low risk of death 24. Nevertheless, the justification 
for the 25% threshold was not provided by the guideline committee and seems therefore 
arbitrary. . In contrast, experts were supportive of high-dose amoxicillin treatment, which is 
successful even in most penicillin-resistant pneumococci. Furthermore, the increasing use of 
long-term macrolides in patients with chronic co-morbidities (bronchiectasis, COPD, asthma), 
who are especially prone to CAP, may increase the risk for macrolide-resistant pneumococci 
in these patients.  
 
 
5) Recommendation on sputum and blood culture to be  obtained in patients with 
severe CAP, as well as in all inpatients empiricall y treated for MRSA or P. aeruginosa 
Testing practices of adults hospitalized with CAP varied significantly by geography and 
disease severity and there is a wide discordance between real-life testing practices and 
international guideline recommendations25. Compared to the 2007 CAP guideline, in which 
the cost versus impact on treatment decisions of diagnostic testing was emphasized, the new 
2019 ATS/IDSA CAP guidelines place greater value on microbiological diagnostics. The 
indication for blood and sputum culture was expanded from severe diseases to all inpatients 
that are empirically treated including coverage to non-core pathogens such as MRSA or P. 
aeruginosa. This is a logical necessity, since the recommendation to de-escalate requires the 
identification of the underlying pathogen.  
The increased value of diagnostics was seen as an improvement by most of the experts (9 
out of 14; 64.3 %). However, some critical comments have been made; 7 out of 14 (50.0 %) 
experts suggested that this recommendation did not go far enough, compared to usual 
practice in other countries, such as UK 26, Germany27 or Japan 28, where blood and sputum 
cultures are required for all in-patients. Furthermore, the limitation mentioned above was 
seen critical by some experts since the “strong” recommendation implies that is appropriate 
for quality assessment and public reporting. This will be a major change in emergency 
department workflow and there was concern among the panel that it may result in poor 
quality specimens. In addition, there was concern that decisions about which diagnostic tests 
to order are often made prior to antibiotic and ICU admission decisions, making these 
recommendations logistically impractical due to the conditional nature on these other 









6) Other areas considered as substantial change by individual experts 
Other changes of recommendation that were mentioned favorably by some experts included 
recommendation against using anaerobic coverage for suspected aspiration (2 out of 14; 
14.3 %) recommendation for urinary antigen testing (1 out of 14; 7.1 %) and the stronger 
evidence in favor of beta-lactam/macrolide combination for severe CAP (1 out of 14; 7.1 %). 
 
Other various items that experts viewed as omissions or inadequately addressed included 
the recommendation to use antibiotics with antivirals for influenza in the outpatient setting (3 
out of 14; 21.4 %) the overall lack of emphasis on the role of antibiotic stewardship (1 out of 
14; 7,1 %) or on CAP prevention by vaccination and smoking cessation (1 out of 14; 7.1 %). 
Furthermore, (1 out of 14; 7.1 %) experts doubted that the general recommendation to use 













Recommendations that are difficult to implement in a context outside of the USA 
 
This section reflects the answers to question #3, which regarded three issues: epidemiology 
and subsequent treatment recommendations as well availability and usage of diagnostic 
methods. 
 
Epidemiology and empiric treatment. Several experts from Northern and Central 
European countries, as well as those from South Africa stated that due to the low incidence 
of CA-MRSA , this organism should not be covered empirically (5 out of 14; 35.7 %)10. In 
contrast, the rate of macrolide (e.g. in Japan, Spain) - and to a lesser degree doxycycline 
(South Africa) - resistant pneumococci was mentioned as a significant problem with 
subsequently opposing macrolide (and doxycycline) monotherapy in outpatients. Experts 
from Africa and South America were not in favor for the recommendation of fluoroquinolones 
even as an alternative for outpatients in their countries and other regions with high 
tuberculosis incidence (6 out of 14; 42.9 %) due to concern for obscuring the diagnosis of 
underlying tuberculosis or NTM infection. Indeed, there are some studies suggesting that 
fluoroquinolones can delay the diagnosis for tuberculosis by several months. Vice-versa, the 
widespread use of fluoroquinolones in MDR-tuberculosis was linked to an increase in 
fluoroquinolone-resistant pneumococci in a report from South Africa29. Two experts (2 out of 
14; 14.3 %) did not agree with the recommendation against follow up chest imaging but did 
not elaborate why. 
 
Diagnostics. Experts from some countries mentioned that molecular diagnostics (e.g. 
influenza PCR and MRSA-PCR from nasal swabs) is not widely available in their countries (2 
out of 14; 14.3 %). However, several experts referred to their national guidelines that valued 
sputum samples higher, and would not restrict them to patients with risk for MRSA and/or 
P. aeruginosa (4 out of 14, 28,6 %).  
 
Discussion 
Although most physicians are aware of limitations to the generalization of guidelines in 
infectious disease, the ATS/IDSA Guidelines for the management of CAP in adults 
nevertheless remain influential, globally and are frequently applied for better or worse outside 
the United States. This issue is well highlighted by the consequences of the “HCAP”-concept 
leading to significant overestimation of MDRO incidence and therefore overtreatment, 
complicated by possible antibiotic resistance and adverse outcomes. Therefore, these 








readership to limitations and geographic-specific caveats of the guidelines. 
 
In summary, additions to the updated CAP guidelines that were welcomed by international 
pneumonia experts included the abandonment of the concept of HCAP, to rate more 
restrictive indications for empiric macrolide treatment in outpatients, increased emphasis on 
microbiological diagnostics in an expanded populations, and addressing the use of 
corticosteroids. Main criticisms included the somewhat arbitrary choice of a 25% resistance 
threshold for outpatient macrolide monotherapy, recommendation of fluoroquinolones as an 
alternative option in areas with elevated mycobacterial prevalence. In addition, a minority of 
experts was strictly against the categorical and simplistic rejection of adjunct corticosteroids 
without acknowledgement of a possible benefit in selected populations with severe CAP. 
Finally, we recognized that the 2019 ATS/IDSA CAP Guidelines were not developed for the 
management of immunocompromised patients, despite the fact that these patients may 
comprise as many as 18% of CAP admissions worldwide30. An international position paper of 
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Table 1. Major changes in recommendations from the 2007 to the 2019 American Thoracic 
Society/Infectious Diseases Society of America Community-Acquired Pneumonia 
Guidelines 
 
Recommendation  2007 ATS/IDSA Guideline  2019 ATS/IDSA Guideline 
 
Sputum culture   Primarily recommended in   Now recommended in patients with 
    patients with severe disease  severe disease as well as in all inpatients 
empirically treated for MRSA or 
Pseudomonas aeruginosa 
 
Blood culture   Primarily recommended in  Now recommended in patients with  
patients with severe disease   severe 
         disease as well as in all inpatients. 
empirically treated for MRSA or P. 
aeruginosa 
 
Macrolide monotherapy  Strong recommendation for   Conditional recommendation  
outpatients    for outpatients based on  
     resistance levels 
     
 
Use of procalcitonin  Not covered    Not recommended to determine  
         need for initial antibacterial therapy 
 
Use of corticosteroids  Not covered    Recommended not to use. May be  
         Considered in patients with  
         refractory septic shock 
 
Use of healthcare-  Accepted as introduced in the 2005 Recommend abandoning this  
associated pneumonia   ATS/IDSA hospital-acquired and categorization. Emphasis on local  
category   ventilator-associated pneumonia epidemiology and validated risk  
    guidelines    factors to determine need for 
MRSA or P. aeruginosa coverage. 
Increased emphasis on deescalation of 
treatment if cultures are negative 
 
Standard empiric therapy  β-Lactam/macrolide and  Both accepted but stronger  
for severe CAP   β-lactam/fluoroquinolone combi- evidence in favor 
nations given equal weighting  of β-lactam/macrolide combination 
 
Routine use of follow-up  Not addressed    Recommended not to obtain.  
chest imaging        Patients may be eligible for lung  
         cancer screening, which 
         should be performed as clinically  










Definition of abbreviations: ATS = American Thoracic Society, CAP= community-acquired pneumonia; IDSA = Infectious Diseases 
Society of America; MRSA = methicillin-resistant Staphylococcus aureus. 
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